Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment

Biomaterials

Volumn 108, Issue , 2016, Pages 44-56

  Song, Xu ^a   Wan, Zhuoya ^a   Chen, Tijia ^a   Fu, Yao ^a   Jiang, Kejun ^a   Yi, Xiaoli ^a   Ke, Huan ^a   Dong, Jianxia ^a   Yang, Liuqing ^a   Li, Lin ^a   Sun, Xun ^a   Gong, Tao ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

iRGD; Legumain; nRGD; Tumor associated macrophage; Tumor microenvironment

Indexed keywords

AMINO ACIDS; CHEMOTHERAPY; DISEASES; ENDOTHELIAL CELLS; LIPOSOMES; MACROPHAGES; PEPTIDES;

IRGD; LEGUMAIN; NRGD; TUMOR ASSOCIATED MACROPHAGES; TUMOR MICROENVIRONMENT;

TUMORS;

ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; DOXORUBICIN; ENDOGLIN; INTERLEUKIN 10; INTERLEUKIN 6; IRGD PEPTIDE; LIPOSOME; MONOCYTE CHEMOTACTIC PROTEIN 1; NRGD PEPTIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR; ANTINEOPLASTIC ANTIBIOTIC; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARDIOTOXICITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COVALENT BOND; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LIPOSOMAL DELIVERY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE CONTRACTION; NEPHROTOXICITY; NONHUMAN; PEPTIDE SYNTHESIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING; SYNTHESIS; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; PROTEIN ENGINEERING; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84989807124     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.09.001     Document Type: Article

References (56)

1. [1] Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Girard, O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer cell 16 (2009), 510–520.
2. [2] Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Greenwald, D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328 (2010), 1031–1035.
3. [3] Puig-Saus, C., Rojas, L.A., Laborda, E., Figueras, A., Alba, R., Fillat, C., et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 21 (2014), 767–774.
4. [4] Dai, W., Fan, Y., Zhang, H., Wang, X., Zhang, Q., A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Drug Deliv. 22 (2015), 10–20.
5. [5] Shen, J., Meng, Q., Sui, H., Yin, Q., Zhang, Z., Yu, H., et al. iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol. Pharm. 11 (2014), 2579–2591.
6. [6] Squadrito, M.L., De Palma, M., Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. aspects Med. 32 (2011), 123–145.
7. [7] Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer cell 19 (2011), 512–526.
8. [8] Lu-Emerson, C., Snuderl, M., Kirkpatrick, N.D., Goveia, J., Davidson, C., Huang, Y., et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-oncology 15 (2013), 1079–1087.
9. [9] Alberici, L., Roth, L., Sugahara, K.N., Agemy, L., Kotamraju, V.R., Teesalu, T., et al. De novo design of a tumor-penetrating peptide. Cancer Res. 73 (2013), 804–812.
10. [10] Liu, Z., Xiong, M., Gong, J., Zhang, Y., Bai, N., Luo, Y., et al. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat. Commun., 5, 2014, 4280.
11. [11] Reisfeld, R.A., The tumor microenvironment: a target for combination therapy of breast cancer. Crit. Rev. Oncog. 18 (2013), 115–133.
12. [12] Lin, Y., Wei, C., Liu, Y., Qiu, Y., Liu, C., Guo, F., Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci. 104 (2013), 1217–1225.
13. [13] Liao, D., Liu, Z., Wrasidlo, W., Chen, T., Luo, Y., Xiang, R., et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine : nanotechnology. Biol. Med. 7 (2011), 665–673.
14. [14] Zhang, X., Zhang, Q., Peng, Q., Zhou, J., Liao, L., Sun, X., et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials 35 (2014), 6130–6141.
15. [15] Chen, Y.-C., Lo, C.-L., Lin, Y.-F., Hsiue, G.-H., Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials 34 (2013), 1115–1127.
16. [16] Haran, G., Cohen, R., Bar, L.K., Barenholz, Y., Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica Biophysica Acta (BBA) Biomembranes 1151 (1993), 201–215.
17. [17] Zhang, X., Zhang, Q., Peng, Q., Zhou, J., Liao, L., Sun, X., et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials 35 (2014), 6130–6141.
18. [18] Chen, S., Li, X.F., Lu, D., Xu, Y.X., Mou, W.J., Wang, L.N., et al. SOX2 regulates apoptosis through MAP4K4-Survivin signaling pathway in human lung cancer cells. Carcinogenesis 35 (2014), 613–623.
19. [19] Liu, Z., Lv, D., Liu, S., Gong, J.B., Wang, D., Xiong, M., et al. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast Cancer in mice. PloS One, 8, 2013.
20. [20] Savaraj, N., Feun, L.G., Lu, K., Gray, K., Wang, C., Loo, T.L., Pharmacology of intrathecal VP-16-213 in dogs. J. Neuro-Oncology 13 (1992), 211–215.
21. [21] Zhu, Z., Li, Y., Li, X., Li, R., Jia, Z., Liu, B., et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J. Control. Release Official J. Control. Release Soc. 142 (2010), 438–446.
22. [22] Wang, K., Zhang, X., Liu, Y., Liu, C., Jiang, B., Jiang, Y., Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 35 (2014), 8735–8747.
23. [23] Liu, Y., Ran, R., Chen, J., Kuang, Q., Tang, J., Mei, L., et al. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35 (2014), 4835–4847.
24. [24] Wu, W., Chen, H., Shan, F., Zhou, J., Sun, X., Zhang, L., et al. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery. Mol. Pharm. 11 (2014), 3378–3385.
25. [25] Xu, Z., Wang, Y., Zhang, L., Huang, L., Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 8 (2014), 3636–3645.
26. [26] Roberts, W.G., Ung, E., Whalen, P., Cooper, B., Hulford, C., Autry, C., et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 68 (2008), 1935–1944.
27. [27] Li, N., Yi, Q., Luo, K., Guo, C., Pan, D., Gu, Z., Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials 35 (2014), 9529–9545.
28. [28] Urruticoechea, A., Smith, I.E., Dowsett, M., Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 23 (2005), 7212–7220.
29. [29] Joensuu, K., Leidenius, M., Kero, M., Andersson, L.C., Horwitz, K.B., Heikkila, P., ER, pr, HER2, Ki-67 and CK5 in early and late relapsing breast Cancer-Reduced CK5 expression in metastases. Breast Cancer Basic Clin. Res. 7 (2013), 23–34.
30. [30] Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002), 549–555.
31. [31] Martinez, F.O., Sica, A., Mantovani, A., Locati, M., Macrophage activation and polarization. Front. Biosci Landmrk 13 (2008), 453–461.
32. [32] Solinas, G., Germano, G., Mantovani, A., Allavena, P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86 (2009), 1065–1073.
33. [33] Tamada, K., Chen, L.P., Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol. Immun. 55 (2006), 355–362.
34. [34] Yao, Y.Z., Pan, Y.M., Chen, J., Sun, X.T., Qiu, Y.D., Ding, Y.T., Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann. Clin. Lab. Sci. 37 (2007), 39–48.
35. [35] Coffelt, S.B., Hughes, R., Lewis, C.E., Tumor-associated macrophages: effectors of angiogenesis and tumor progression. BBA Rev Cancer 1796 (2009), 11–18.
36. [36] Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
37. [37] Adeegbe, D.O., Nishikawa, H., Natural and induced T regulatory cells in cancer. Front. Immunol., 4, 2013, 190.
38. [38] Pollard, J.W., Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004), 71–78.
39. [39] Lievense, L.A., Bezemer, K., Aerts, J.G., Hegmans, J.P., Tumor-associated macrophages in thoracic malignancies. Lung Cancer 80 (2013), 256–262.
40. [40] Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
41. [41] Gehl, J., Boesgaard, M., Paaske, T., Vittrup Jensen, B., Dombernowsky, P., Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol. Official J. Eur. Soc. Med. Oncology/ESMO 7 (1996), 687–693.
42. [42] Liu, Y., Bajjuri, K.M., Liu, C., Sinha, S.C., Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug. Mol. Pharm. 9 (2012), 168–175.
43. [43] Liu, Y., Goswami, R.K., Liu, C., Sinha, S.C., Chemically programmed bispecific antibody targeting legumain protease and alphavbeta3 integrin mediates strong antitumor effects. Mol. Pharm. 12 (2015), 2544–2550.
44. [44] Liu, C., Sun, C., Huang, H., Janda, K., Edgington, T., Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63 (2003), 2957–2964.
45. [45] Chen, Y., Zhang, W., Huang, Y., Gao, F., Fang, X., Dual-functional c(RGDyK)-decorated Pluronic micelles designed for antiangiogenesis and the treatment of drug-resistant tumor. Int. J. Nanomedicine 10 (2015), 4863–4881.
46. [46] Zhu, Z., Xie, C., Liu, Q., Zhen, X., Zheng, X., Wu, W., et al. The effect of hydrophilic chain length and iRGD on drug delivery from poly(epsilon-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles. Biomaterials 32 (2011), 9525–9535.
47. [47] von Boehmer, H., Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6 (2005), 338–344.
48. [48] Liu, Z.Q., Kim, J.H., Falo, L.D., You, Z.Y., Tumor regulatory T cells potently abrogate antitumor immunity. J. Immunol. 182 (2009), 6160–6167.
49. [49] Wu, W., Luo, Y., Sun, C., Liu, Y., Kuo, P., Varga, J., et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 66 (2006), 970–980.
50. [50] Niu, M., Valdes, S., Naguib, Y.W., Hursting, S.D., Cui, Z., Tumor-associated macrophage-mediated targeted therapy of triple-negative breast Cancer. Mol. Pharm. 13 (2016), 1833–1842.
51. [51] Yan, Z., Wang, F., Wen, Z., Zhan, C., Feng, L., Liu, Y., et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J. Control. Release Official J. Control. Release Soc. 157 (2012), 118–125.
52. [52] Vieira, A.C., Chaves, L.L., Pinheiro, M., Ferreira, D., Sarmento, B., Reis, S., Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells. Int. J. Nanomedicine 11 (2016), 2601–2617.
53. [53] Chen, J., Son, H.N., Hill, J.J., Srinivasan, S., Su, F.Y., Stayton, P.S., et al. Nanostructured glycopolymer augmented liposomes to elucidate carbohydrate-mediated targeting. Nanomed. Nanotechnol. Biol. Med. 12 (2016), 2031–2041.
54. [54] Meenakshi, J., Anupama, Goswami, S.K., Datta, K., Constitutive expression of hyaluronan binding protein 1 (HABP1/p32/gC1qR) in normal fibroblast cells perturbs its growth characteristics and induces apoptosis. Biochem. Biophysical Res. Commun. 300 (2003), 686–693.
55. [55] Jha, B.K., Salunke, D.M., Datta, K., Disulfide bond formation through Cys186 facilitates functionally relevant dimerization of trimeric hyaluronan-binding protein 1 (HABP1)/p32/gC1qR. Eur. J. Biochemistry/FEBS 269 (2002), 298–306.
56. [56] Saha, P., Chowdhury, A.R., Dutta, S., Chatterjee, S., Ghosh, I., Datta, K., Autophagic vacuolation induced by excess ROS generation in HABP1/p32/gC1qR overexpressing fibroblasts and its reversal by polymeric hyaluronan. PloS One, 8, 2013, e78131.